Paul F Worley

US Patent:

6436673, Aug 20, 2002

Filed:

Jun 16, 1998

Appl. No.:

09/098358

Inventors:

Paul Worley - Baltimore MD
Cynthia Tsui - Baltimore MD

Assignee:

The Johns Hopkins University School of Medicine - Baltimore MD

International Classification:

C12N 1518

US Classification:

435 694, 4353201, 435325, 4352523, 536 2351

Abstract:

A novel neuronal cell growth factor, neuronal-activity regulated pentraxin, Narp, is provided, as well as polynucleotides encoding Narp. Narp is useful for induction of dendritic neurite outgrowth as well as promotion of neuronal migration. Methods for treatment of subjects having a neuronal cell disorder, utilizing Narp of the invention, are also provided.

US Patent:

6699660, Mar 2, 2004

Filed:

Feb 5, 1999

Appl. No.:

09/244805

Inventors:

Paul F. Worley - Baltimore MD
Anthony Lanahan - Baltimore MD
Bernhard Goetz - Heidelberg, DE
Holger Hiemisch - Heidelberg, DE
Rohini Kuner - Heidelberg, DE
Sigrid Scheek - Dossenheim, DE
Karoly Nikolich - Redwood City CA
Eugene Zhukovsky - San Francisco CA

Assignee:

The Johns Hopkins University School of Medicine - Baltimore MD

International Classification:

C12N 1563

US Classification:

435 6, 4353201, 435325, 536 235

Abstract:

The present invention provides methods and materials related to immediate early genes. Specifically, the invention provides isolated immediate early gene nucleic acid, cells that contain isolated immediate early gene nucleic acid, substantially pure polypeptides encoded by immediate early gene nucleic acid, and antibodies having specific binding affinity for a polypeptide encoded by immediate early gene nucleic acid. In addition, the invention provides cDNA libraries enriched for immediate early genes cDNAs, isolated nucleic acid derived from such cDNA libraries, and methods for treating conditions related to a deficiency in a neurons immediate early gene responsiveness to a stimulus.

US Patent:

6720175, Apr 13, 2004

Filed:

Aug 18, 1999

Appl. No.:

09/377285

Inventors:

Paul F. Worley - Baltimore MD
Jian Cheng Tu - Baltimore MD
Bo Xiao - Ellicott City MD
Daniel Leahy - Baltimore MD
Jutta Beneken - Baltimore MD
Anthony A. Lanahan - Baltimore MD
Paul R. Brakeman - Baltimore MD

Assignee:

The Johns Hopkins University School of Medicine - Baltimore MD

International Classification:

C07H 2104

US Classification:

4352523, 536 235, 536 231, 43525411, 435325, 4353201

Abstract:

A method is provided for identifying a compound that modulates a cellular response associated with Homer and mediated by a cell-surface or an intracellular receptor. A method is further provided for identifying a compound that modulates receptor activated calcium mobilization associated with Homer. A method is provided for identifying a compound that inhibits Homer protein activity based on the crystal structure coordinates of Homer protein binding domain. A method is also provided for identifying a compound that affects the formation of cell surface receptors into clusters. Also provided are nucleic acids encoding Homer proteins as well as Homer proteins, and Homer interacting proteins.

US Patent:

6780600, Aug 24, 2004

Filed:

Jul 20, 2001

Appl. No.:

09/910706

Inventors:

Paul F. Worley - Baltimore MD
Paul R. Brakeman - San Francisco CA

Assignee:

The Johns Hopkins University School of Medicine - Baltimore MD

International Classification:

G01N 3353

US Classification:

435 71, 435 75, 435 78, 435 79, 435 791, 435 792, 435 793, 435 794, 435 795

Abstract:

Disclosed are nucleotide coding sequences and polypeptide sequences for synaptic activation binding proteins that are characterized by induction in the central nervous system following neuronal activity in rat hippocampus. Such proteins are identified by (i) substantial homology at the nucleotide or protein sequence level to specifically defined rat, human or mouse coding sequences or proteins, (ii) ability to bind to and affect the activity of effector proteins in the CNS, such as metabotropic glutamate receptors, (iii) binding specificity for a particular binding sequence, and (iv) presence in the sequence of a PDZ-like domain. Nucleotides and polypeptides of the invention are useful in screening and diagnostic assays.

US Patent:

6864083, Mar 8, 2005

Filed:

Jul 9, 2002

Appl. No.:

10/192381

Inventors:

Paul F. Worley - Baltimore MD, US
Jian Cheng Tu - Baltimore MD, US
Bo Xiao - Ellicott City MD, US
Daniel Leahy - Baltimore MD, US
Jutta Beneken - Baltimore MD, US
Anthony A. Lanahan - Baltimore MD, US
Paul R. Brakeman - Baltimore MD, US

International Classification:

C07H021/04
C12N001/20
C12N005/00
C12N007/01
C12N015/00

US Classification:

4352523, 43525411, 435325, 4353201, 536 231, 536 235

Abstract:

A method is provided for identifying a compound that modulates a cellualr response associate with Homer and mediated by a cell-surface or an intracellular receptor. A method is further provided for identifying a compound that modulates receptor activated calcium mobilization associated with Homer. A method is provided for identifying a compound that inhibits Homer protein activity based on the crystal structure coordinates of Homer protein binding domain. A method is also provided for identifying a compound that affects the formation of cell surface receptors into clusters. Also provided are nucleic acids encoding Homer proteins as well as Homer proteins, and Homer interacting proteins.

US Patent:

7217525, May 15, 2007

Filed:

Nov 18, 2002

Appl. No.:

10/299957

Inventors:

Paul Worley - Baltimore MD, US
Richard O'Brien - Baltimore MD, US
DeSheng Xu - Towson MD, US
Richard L. Huganir - Baltimore MD, US

Assignee:

The Johns Hopkins University School of Medicine - Baltimore MD

International Classification:

G01N 33/567
G01N 33/53
C12Q 1/68

US Classification:

435 71, 435 6, 435 721

Abstract:

A method is provided for identifying a compound which affects the formation of AMPA receptors into aggregates. The method also provides for a compound, for example, a long pentraxin polypeptide or fragment thereof, having a pentraxin binding domain and affecting AMPA receptor aggregation. The method provided herein affects AMPA receptor aggregation of GluR1, GluR2 and GluR3 receptor subunits.

US Patent:

7378498, May 27, 2008

Filed:

Dec 10, 2004

Appl. No.:

11/008889

Inventors:

Paul F. Worley - Baltimore MD, US
Jian Cheng Tu - Baltimore MD, US
Bo Xiao - Ellicott City MD, US
Daniel Leahy - Baltimore MD, US
Jutta Beneken - Baltimore MD, US
Anthony A. Lanahan - Baltimore MD, US
Paul R. Brakeman - Baltimore MD, US

Assignee:

The Johns Hopkins University School of Medicine - Baltimore MD

International Classification:

C07K 14/435
C07H 21/04

US Classification:

530350, 530300, 536 231, 536 235

Abstract:

A method is provided for identifying a compound that modulates a cellualr response associated with Homer and mediated by a cell-surface or an intracellular receptor. A method is further provided for identifying a compound that modulates receptor activated calcium mobilization associated with Homer. A method is provided for identifying a compound that inhibits Homer protein activity based on the crystal structure coordinates of Homer protein binding domain. A method is also provided for identifying a compound that affects the formation of cell surface receptors into clusters. Also provided are nucleic acids encoding Homer proteins as well as Homer proteins, and Homer interacting proteins.

US Patent:

7399830, Jul 15, 2008

Filed:

Jun 10, 2004

Appl. No.:

10/866256

Inventors:

Paul F. Worley - Baltimore MD, US
Paul R. Brakeman - San Francisco CA, US

Assignee:

Johns Hopkins University - Baltimore MD

International Classification:

C07K 14/435

US Classification:

530350

Abstract:

Disclosed are nucleotide coding sequences and polypeptide sequences for synaptic activation binding proteins that are characterized by induction in the central nervous system following neuronal activity in rat hippocampus. Such proteins are identified by (i) substantial homology at the nucleotide or protein sequence level to specifically defined rat, human or mouse coding sequences or proteins, (ii) ability to bind to and affect the activity of effector proteins in the CNS, such as metabotropic glutamate receptors, (iii) binding specificity for a particular binding sequence, and (iv) presence in the sequence of a PDZ-like domain. Nucleotides and polypeptides of the invention are useful in screening and diagnostic assays.

Author:

Paul Worley

ISBN #:

0195516508

Author:

Paul Worley

ISBN #:

1930907796